LGL Partners’s Sarepta Therapeutics SRPT Stock Holding History

LGL Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,196	Closed	-$543K	–	120
2024 Q1	$543K	Hold	4,196	–	–	0.09%	66
2023 Q4	$405K	Hold	4,196	–	–	0.06%	75
2023 Q3	$509K	Buy	4,196 +186	+5%	+$21K	0.09%	65
2023 Q2	$459K	Buy	4,010 +370	+10%	+$47.7K	0.08%	72
2023 Q1	$502K	Sell	3,640 -346	-9%	-$44.9K	0.09%	62
2022 Q4	$517K	Sell	3,986 -25	-0.6%	-$2.9K	0.09%	55
2022 Q3	$443K	Buy	+4,011	New	+$404K	0.09%	68
2017 Q3	–	Sell	-8,887	Closed	-$300K	–	84
2017 Q2	$300K	Hold	8,887	–	–	0.16%	72
2017 Q1	$263K	Hold	8,887	–	–	0.13%	76
2016 Q4	$244K	Hold	8,887	–	–	0.13%	84
2016 Q3	$542K	Sell	8,887 -3,975	-31%	-$120K	0.28%	42
2016 Q2	$269K	Sell	12,862 -12,000	-48%	-$222K	0.15%	81
2016 Q1	$485K	Buy	24,862 +1,000	+4%	+$17.5K	0.25%	53
2015 Q4	$921K	Buy	+23,862	New	+$774K	0.5%	35

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGL Partners's SRPT Position: Q2 2024 in Review

LGL Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 4,196 shares — an estimated $543K sold.

LGL Partners first reported a position in SRPT in Q4 2015 and held it in 14 quarters. The position peaked at $921K in Q4 2015. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

LGL Partners reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
LGL Partners sold 4,196 Sarepta Therapeutics shares in Q2 2024, an estimated $543K.
LGL Partners first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 14 quarters.
LGL Partners's Sarepta Therapeutics position peaked at $921K in Q4 2015.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on LGL Partners's 13F filing for Q2 2024, filed 1 Aug 2024.